{"product_id":"cst-63132t","title":"CST,  63132T, FCN3 (F9E8J) Rabbit Monoclonal Antibody","description":"Monoclonal Antibody for studying FCN3. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, FCN3 (F9E8J) Rabbit Monoclonal Antibody (CST #63132) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nWestern Blotting: 1:1000\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg\/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Western Blotting\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nFCN3 (F9E8J) Rabbit Monoclonal Antibody recognizes endogenous levels of total FCN3 protein.\nSpecies Reactivity: Human\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nMonoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala236 of human FCN3 protein.\n\u003cb\u003eBackground\u003c\/b\u003e\nThe complement system plays a critical role in the innate immune response to infection (1-3). Three distinct pathways, the classical, alternative, and lectin pathways, work to regulate complement (2). In humans, there are four recognition proteins in the lectin pathway: mannose-binding lectin (MBL) and 3 ficolin proteins, FCN1, FCN2, and FCN3 (1,2). Ficolin-3 (FCN3) was originally identified as the Hakata antigen, a macroglycoprotein that showed reactivity with serum from systemic lupus erythematosus (SLE) patients (1,5,6). FCN3 contains an N-terminal collagen-like domain that mediates oligomerization, and a C-terminal fibrinogen-like domain that binds to N-acetyl compounds found on the surfaces of microorganisms, resulting in complement activation (2). This activation generates complexes that disrupt and destroy abnormal cells. Complement fragments interact with immune cells, such as macrophages, neutrophils, and dendritic cells; these interactions enhance chemotaxis, phagocytic capacity, and antigen-presentation, boosting adaptive immunity (2,3). Accordingly, dysregulation in complement pathways has been shown to correlate with susceptibility to infection and autoimmunity (3-6). FCN3 is highly expressed in the lung and liver. Recent work has focused on the role of FCN3 in cancers (7-9). FCN3 is downregulated in lung and esophageal tumors (7,8). In analysis of FCN3 in serum from hepatocellular carcinoma (HCC) patients, low expression was associated with poor prognosis (9).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nCollagen\/fibrinogen domain-containing lectin 3 p35; Collagen\/fibrinogen domain-containing protein 3; FCN3; FCNH; ficolin (collagen\/fibrinogen domain containing) 3 (Hakata antigen); ficolin 3; Ficolin-3; H-ficolin; HAKA1; Hakata antigen\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H\nSENSITIVITY: Endogenous\nMW (kDa): 33\nSource\/Isotype: Rabbit IgG","brand":"CST","offers":[{"title":"Default Title","offer_id":46801032577193,"sku":"63132T","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-63132t","provider":"Iright","version":"1.0","type":"link"}